{"id":2732,"date":"2023-05-04T15:48:07","date_gmt":"2023-05-04T15:48:07","guid":{"rendered":"https:\/\/blog.trive.com\/?p=2732"},"modified":"2023-05-04T15:48:08","modified_gmt":"2023-05-04T15:48:08","slug":"its-healthy-earnings-and-an-unhealthy-outlook-for-cvs-health-corporation","status":"publish","type":"post","link":"https:\/\/blog.trive.com\/es\/inversion\/its-healthy-earnings-and-an-unhealthy-outlook-for-cvs-health-corporation\/","title":{"rendered":"Son ganancias saludables y una perspectiva poco saludable para CVS Health Corporation"},"content":{"rendered":"<p>CVS Health Corporation (ISIN: US1266501006) agarr\u00f3 por la garganta el primer trimestre de 2023, lo que se tradujo en un resultado de beneficios optimista. Las ganancias y los ingresos superaron las expectativas de Wall Street en un 4,59% y un 5,69%, respectivamente, con un beneficio por acci\u00f3n de $2.20 y unos ingresos de $84.280 millones.<\/p>\n\n\n\n<p>Sin embargo, los buenos resultados no bastaron para impulsar la cotizaci\u00f3n de CVS, que baj\u00f3 un 3,60% debido a la debilidad de sus perspectivas. Los recientes esfuerzos de expansi\u00f3n de CVS han dejado un agujero en sus saldos de caja y es probable que reduzcan los beneficios a medida que el coste de las adquisiciones se filtre a trav\u00e9s de la cuenta de resultados.<\/p>\n\n\n\n<p>CVS entra en la categor\u00eda de valores defensivos debido a la necesidad de los servicios sanitarios de la empresa. Ante la posibilidad de una recesi\u00f3n en la segunda mitad de 2023, el precio de las acciones de CVS probablemente se mantendr\u00e1 firme a medida que los beneficios se mantengan estables, independientemente de la situaci\u00f3n general del mercado burs\u00e1til y de la econom\u00eda.<\/p>\n\n\n\n<h2>T\u00e9cnicos<\/h2>\n\n\n\n<p>La cotizaci\u00f3n de CVS cedi\u00f3 ante los inversores bajistas durante la mayor parte de 2022, ya que las subidas de los tipos de inter\u00e9s devaluaron la renta variable y el aumento de los costes de endeudamiento redujo los beneficios al tiempo que limitaba las perspectivas de crecimiento. La tendencia bajista fue validada por el precio de la acci\u00f3n que cruz\u00f3 por debajo de la media m\u00f3vil de 100 d\u00edas mientras formaba un patr\u00f3n de canal descendente. El soporte y la resistencia se establecieron en los niveles de $68.22 y $104.02 por acci\u00f3n, respectivamente.<\/p>\n\n\n\n<p>Con los inversores bajistas al mando, la cotizaci\u00f3n de CVS podr\u00eda seguir bajando. El soporte en el nivel de $68.22 por acci\u00f3n podr\u00eda ser interesante para los inversores alcistas que busquen posiciones largas. Es probable que se produzca un retroceso si se respeta el nivel de soporte. Si se comprometen al alza, es probable que los inversores alcistas busquen el nivel de $104.02 por acci\u00f3n como punto de salida.<\/p>\n\n\n\n<p>Alternativamente, si el precio de la acci\u00f3n rompe el nivel de soporte en vol\u00famenes altos, podr\u00eda se\u00f1alar la intenci\u00f3n del mercado de llevar el precio de la acci\u00f3n a\u00fan m\u00e1s bajo. El siguiente punto de inter\u00e9s probable para las oportunidades de compra ser\u00e1 el soporte del nivel de $54.72 por acci\u00f3n.<\/p>\n\n\n\n<p>Si la cotizaci\u00f3n se acerca al nivel de $68.22 o $54.72 por acci\u00f3n con vol\u00famenes decrecientes, podr\u00eda indicar la desaparici\u00f3n del impulso bajista y la probabilidad de un cambio de tendencia.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><img decoding=\"async\" loading=\"lazy\" width=\"848\" height=\"494\" src=\"https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/05\/040523_CVS.png\" alt=\"\" class=\"wp-image-2733\" srcset=\"https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/05\/040523_CVS.png 848w, https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/05\/040523_CVS-300x175.png 300w, https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/05\/040523_CVS-768x447.png 768w, https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/05\/040523_CVS-18x10.png 18w\" sizes=\"(max-width: 848px) 100vw, 848px\" \/><\/figure>\n\n\n\n<h2>Fundamentales<\/h2>\n\n\n\n<p>CVS disfrut\u00f3 de un trimestre saludable, en el que todos los segmentos de negocio registraron un crecimiento de los ingresos, desde los seguros de salud hasta las farmacias. Las ventas aumentaron un 11%, hasta $85.300 millones, frente a los $76.800 millones de hace un a\u00f1o.<\/p>\n\n\n\n<p>El crecimiento de los ingresos se vio impulsado principalmente por la expansi\u00f3n de la afiliaci\u00f3n a planes de salud de CVS, que aument\u00f3 en 1.1 millones, alcanzando los 25.5 millones a 31 de marzo de 2023. El resultado fue un aumento del 12% en los ingresos del segmento, hasta $25.800 millones en el primer trimestre.<\/p>\n\n\n\n<p>El crecimiento de sus afiliados a planes de salud mantuvo los resultados de CVS por encima de la marca de los $2.000 millones, pero fueron inferiores a los del primer trimestre del a\u00f1o pasado en un 9%, hasta los $2.140 millones. Los gastos de explotaci\u00f3n totales crecieron un 12%, ya que los costes de producci\u00f3n aumentaron en consonancia con el mejor comportamiento de las ventas.<\/p>\n\n\n\n<p>Sin embargo, no se prev\u00e9 que este buen trimestre se extienda a otros trimestres, ya que los esfuerzos de expansi\u00f3n de CVS aumentar\u00e1n los costes y pesar\u00e1n en los futuros resultados trimestrales. Se espera que el gran gasto de la empresa, de casi $18.000 millones, para adquirir Signify Health y Oak Street Health afecte a los beneficios futuros.<\/p>\n\n\n\n<p>Una vez descontados los flujos de caja futuros, se espera que el valor razonable de CVS sea de $75.55 por acci\u00f3n, lo que deja margen para una subida del 7,54% si los inversores alcistas comienzan a invertir en el valor.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><img decoding=\"async\" loading=\"lazy\" width=\"874\" height=\"458\" src=\"https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/05\/040523_CVS1.png\" alt=\"\" class=\"wp-image-2734\" srcset=\"https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/05\/040523_CVS1.png 874w, https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/05\/040523_CVS1-300x157.png 300w, https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/05\/040523_CVS1-768x402.png 768w, https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/05\/040523_CVS1-18x9.png 18w\" sizes=\"(max-width: 874px) 100vw, 874px\" \/><\/figure>\n\n\n\n<p>Dentro de la horquilla de capitalizaci\u00f3n burs\u00e1til de $50.000 a $100.000 millones, CVS es uno de los valores sanitarios mejor valorados. La acci\u00f3n cotiza a m\u00e1s de 20 veces su nivel actual de beneficios, lo que indica su elevado valor percibido por los inversores. Sin embargo, el precio de la acci\u00f3n est\u00e1 alineado con las valoraciones de sus hom\u00f3logos, lo que representa la salud del sector.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><img decoding=\"async\" loading=\"lazy\" width=\"876\" height=\"453\" src=\"https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/05\/040523_CVS3.png\" alt=\"\" class=\"wp-image-2735\" srcset=\"https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/05\/040523_CVS3.png 876w, https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/05\/040523_CVS3-300x155.png 300w, https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/05\/040523_CVS3-768x397.png 768w, https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/05\/040523_CVS3-18x9.png 18w\" sizes=\"(max-width: 876px) 100vw, 876px\" \/><\/figure>\n\n\n\n<p>En comparaci\u00f3n con el S&amp;P500, CVS ha obtenido peores resultados en los \u00faltimos cinco a\u00f1os, a pesar de haber ganado una quinta parte de su valor en ese periodo. Sin embargo, su menor rendimiento puede atribuirse a la rentabilidad superior de los valores tecnol\u00f3gicos y otros valores de crecimiento en comparaci\u00f3n con los valores sanitarios. La empresa sigue representando una inversi\u00f3n saludable, dado su avance expansivo y la mejora prevista de las perspectivas a largo plazo.<\/p>\n\n\n\n<h2>Resumen<\/h2>\n\n\n\n<p>A pesar de anunciar unas perspectivas poco halag\u00fce\u00f1as para lo que queda de 2023, es probable que la cotizaci\u00f3n de CVS Health Corporation se recupere a medio y largo plazo a medida que los efectos de sus recientes adquisiciones de calidad se filtren en mayores ingresos y beneficios al tiempo que se suman a las sinergias de la empresa.<\/p>\n\n\n\n<p><em>Fuentes: CVS Health Corporation, Nasdaq, Reuters, CNBC, Forbes, TradingView, Koyfin<\/em><\/p>","protected":false},"excerpt":{"rendered":"<p>CVS Health Corporation (ISIN: US1266501006) grabbed the first quarter of 2023 by the throat, leading to an upbeat earnings result. Earnings and revenues beat Wall Street Expectations by 4.59% and 5.69%, respectively, with $2.20 earnings per share and $84.28B revenue reported. However, the upbeat earnings were not enough to boost CVS\u2019s share price, which declined [&hellip;]<\/p>","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[2],"tags":[80],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v20.10 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>It\u2019s Healthy Earnings and An Unhealthy Outlook for CVS Health Corporation<\/title>\n<meta name=\"description\" content=\"CVS Health Corporation (ISIN: US1266501006) grabbed the first quarter of 2023 by the throat, leading to an upbeat earnings result. Earnings and revenues beat Wall Street Expectations by 4.59% and 5.69%, respectively, with $2.20 earnings per share and $84.28B revenue reported.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blog.trive.com\/es\/inversion\/its-healthy-earnings-and-an-unhealthy-outlook-for-cvs-health-corporation\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"It\u2019s Healthy Earnings and An Unhealthy Outlook for CVS Health Corporation\" \/>\n<meta property=\"og:description\" content=\"CVS Health Corporation (ISIN: US1266501006) grabbed the first quarter of 2023 by the throat, leading to an upbeat earnings result. Earnings and revenues beat Wall Street Expectations by 4.59% and 5.69%, respectively, with $2.20 earnings per share and $84.28B revenue reported.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blog.trive.com\/es\/inversion\/its-healthy-earnings-and-an-unhealthy-outlook-for-cvs-health-corporation\/\" \/>\n<meta property=\"og:site_name\" content=\"Trive Blog\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-04T15:48:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-05-04T15:48:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/05\/040523_CVS.png\" \/>\n\t<meta property=\"og:image:width\" content=\"848\" \/>\n\t<meta property=\"og:image:height\" content=\"494\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"It\u2019s Healthy Earnings and An Unhealthy Outlook for CVS Health Corporation\" \/>\n<meta name=\"twitter:description\" content=\"CVS Health Corporation (ISIN: US1266501006) grabbed the first quarter of 2023 by the throat, leading to an upbeat earnings result. Earnings and revenues beat Wall Street Expectations by 4.59% and 5.69%, respectively, with $2.20 earnings per share and $84.28B revenue reported.\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/05\/040523_CVS.png\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/blog.trive.com\/es\/inversion\/its-healthy-earnings-and-an-unhealthy-outlook-for-cvs-health-corporation\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/blog.trive.com\/es\/inversion\/its-healthy-earnings-and-an-unhealthy-outlook-for-cvs-health-corporation\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"It\u2019s Healthy Earnings and An Unhealthy Outlook for CVS Health Corporation\",\"datePublished\":\"2023-05-04T15:48:07+00:00\",\"dateModified\":\"2023-05-04T15:48:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/blog.trive.com\/es\/inversion\/its-healthy-earnings-and-an-unhealthy-outlook-for-cvs-health-corporation\/\"},\"wordCount\":714,\"publisher\":{\"@id\":\"https:\/\/blog.trive.com\/#organization\"},\"keywords\":[\"CVS\"],\"articleSection\":[\"Investment\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/blog.trive.com\/es\/inversion\/its-healthy-earnings-and-an-unhealthy-outlook-for-cvs-health-corporation\/\",\"url\":\"https:\/\/blog.trive.com\/es\/inversion\/its-healthy-earnings-and-an-unhealthy-outlook-for-cvs-health-corporation\/\",\"name\":\"It\u2019s Healthy Earnings and An Unhealthy Outlook for CVS Health Corporation\",\"isPartOf\":{\"@id\":\"https:\/\/blog.trive.com\/#website\"},\"datePublished\":\"2023-05-04T15:48:07+00:00\",\"dateModified\":\"2023-05-04T15:48:08+00:00\",\"description\":\"CVS Health Corporation (ISIN: US1266501006) grabbed the first quarter of 2023 by the throat, leading to an upbeat earnings result. Earnings and revenues beat Wall Street Expectations by 4.59% and 5.69%, respectively, with $2.20 earnings per share and $84.28B revenue reported.\",\"breadcrumb\":{\"@id\":\"https:\/\/blog.trive.com\/es\/inversion\/its-healthy-earnings-and-an-unhealthy-outlook-for-cvs-health-corporation\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/blog.trive.com\/es\/inversion\/its-healthy-earnings-and-an-unhealthy-outlook-for-cvs-health-corporation\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/blog.trive.com\/es\/inversion\/its-healthy-earnings-and-an-unhealthy-outlook-for-cvs-health-corporation\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/blog.trive.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"It\u2019s Healthy Earnings and An Unhealthy Outlook for CVS Health Corporation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/blog.trive.com\/#website\",\"url\":\"https:\/\/blog.trive.com\/\",\"name\":\"Trive Blog\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/blog.trive.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/blog.trive.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/blog.trive.com\/#organization\",\"name\":\"Trive Blog\",\"url\":\"https:\/\/blog.trive.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/blog.trive.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/blog.trive.com\/wp-content\/uploads\/2022\/09\/cropped-cropped-trive_horizontal_black_logo.png\",\"contentUrl\":\"https:\/\/blog.trive.com\/wp-content\/uploads\/2022\/09\/cropped-cropped-trive_horizontal_black_logo.png\",\"width\":723,\"height\":199,\"caption\":\"Trive Blog\"},\"image\":{\"@id\":\"https:\/\/blog.trive.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"\",\"url\":\"https:\/\/blog.trive.com\/es\/author\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"It\u2019s Healthy Earnings and An Unhealthy Outlook for CVS Health Corporation","description":"CVS Health Corporation (ISIN: US1266501006) grabbed the first quarter of 2023 by the throat, leading to an upbeat earnings result. Earnings and revenues beat Wall Street Expectations by 4.59% and 5.69%, respectively, with $2.20 earnings per share and $84.28B revenue reported.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blog.trive.com\/es\/inversion\/its-healthy-earnings-and-an-unhealthy-outlook-for-cvs-health-corporation\/","og_locale":"es_ES","og_type":"article","og_title":"It\u2019s Healthy Earnings and An Unhealthy Outlook for CVS Health Corporation","og_description":"CVS Health Corporation (ISIN: US1266501006) grabbed the first quarter of 2023 by the throat, leading to an upbeat earnings result. Earnings and revenues beat Wall Street Expectations by 4.59% and 5.69%, respectively, with $2.20 earnings per share and $84.28B revenue reported.","og_url":"https:\/\/blog.trive.com\/es\/inversion\/its-healthy-earnings-and-an-unhealthy-outlook-for-cvs-health-corporation\/","og_site_name":"Trive Blog","article_published_time":"2023-05-04T15:48:07+00:00","article_modified_time":"2023-05-04T15:48:08+00:00","og_image":[{"width":848,"height":494,"url":"https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/05\/040523_CVS.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_title":"It\u2019s Healthy Earnings and An Unhealthy Outlook for CVS Health Corporation","twitter_description":"CVS Health Corporation (ISIN: US1266501006) grabbed the first quarter of 2023 by the throat, leading to an upbeat earnings result. Earnings and revenues beat Wall Street Expectations by 4.59% and 5.69%, respectively, with $2.20 earnings per share and $84.28B revenue reported.","twitter_image":"https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/05\/040523_CVS.png","twitter_misc":{"Escrito por":"","Tiempo de lectura":"4 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blog.trive.com\/es\/inversion\/its-healthy-earnings-and-an-unhealthy-outlook-for-cvs-health-corporation\/#article","isPartOf":{"@id":"https:\/\/blog.trive.com\/es\/inversion\/its-healthy-earnings-and-an-unhealthy-outlook-for-cvs-health-corporation\/"},"author":{"name":"","@id":""},"headline":"It\u2019s Healthy Earnings and An Unhealthy Outlook for CVS Health Corporation","datePublished":"2023-05-04T15:48:07+00:00","dateModified":"2023-05-04T15:48:08+00:00","mainEntityOfPage":{"@id":"https:\/\/blog.trive.com\/es\/inversion\/its-healthy-earnings-and-an-unhealthy-outlook-for-cvs-health-corporation\/"},"wordCount":714,"publisher":{"@id":"https:\/\/blog.trive.com\/#organization"},"keywords":["CVS"],"articleSection":["Investment"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/blog.trive.com\/es\/inversion\/its-healthy-earnings-and-an-unhealthy-outlook-for-cvs-health-corporation\/","url":"https:\/\/blog.trive.com\/es\/inversion\/its-healthy-earnings-and-an-unhealthy-outlook-for-cvs-health-corporation\/","name":"It\u2019s Healthy Earnings and An Unhealthy Outlook for CVS Health Corporation","isPartOf":{"@id":"https:\/\/blog.trive.com\/#website"},"datePublished":"2023-05-04T15:48:07+00:00","dateModified":"2023-05-04T15:48:08+00:00","description":"CVS Health Corporation (ISIN: US1266501006) grabbed the first quarter of 2023 by the throat, leading to an upbeat earnings result. Earnings and revenues beat Wall Street Expectations by 4.59% and 5.69%, respectively, with $2.20 earnings per share and $84.28B revenue reported.","breadcrumb":{"@id":"https:\/\/blog.trive.com\/es\/inversion\/its-healthy-earnings-and-an-unhealthy-outlook-for-cvs-health-corporation\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blog.trive.com\/es\/inversion\/its-healthy-earnings-and-an-unhealthy-outlook-for-cvs-health-corporation\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/blog.trive.com\/es\/inversion\/its-healthy-earnings-and-an-unhealthy-outlook-for-cvs-health-corporation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blog.trive.com\/"},{"@type":"ListItem","position":2,"name":"It\u2019s Healthy Earnings and An Unhealthy Outlook for CVS Health Corporation"}]},{"@type":"WebSite","@id":"https:\/\/blog.trive.com\/#website","url":"https:\/\/blog.trive.com\/","name":"Trive Blog","description":"","publisher":{"@id":"https:\/\/blog.trive.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blog.trive.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/blog.trive.com\/#organization","name":"Trive Blog","url":"https:\/\/blog.trive.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/blog.trive.com\/#\/schema\/logo\/image\/","url":"https:\/\/blog.trive.com\/wp-content\/uploads\/2022\/09\/cropped-cropped-trive_horizontal_black_logo.png","contentUrl":"https:\/\/blog.trive.com\/wp-content\/uploads\/2022\/09\/cropped-cropped-trive_horizontal_black_logo.png","width":723,"height":199,"caption":"Trive Blog"},"image":{"@id":"https:\/\/blog.trive.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"","url":"https:\/\/blog.trive.com\/es\/author\/"}]}},"_links":{"self":[{"href":"https:\/\/blog.trive.com\/es\/wp-json\/wp\/v2\/posts\/2732"}],"collection":[{"href":"https:\/\/blog.trive.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blog.trive.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blog.trive.com\/es\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/blog.trive.com\/es\/wp-json\/wp\/v2\/comments?post=2732"}],"version-history":[{"count":1,"href":"https:\/\/blog.trive.com\/es\/wp-json\/wp\/v2\/posts\/2732\/revisions"}],"predecessor-version":[{"id":2736,"href":"https:\/\/blog.trive.com\/es\/wp-json\/wp\/v2\/posts\/2732\/revisions\/2736"}],"wp:attachment":[{"href":"https:\/\/blog.trive.com\/es\/wp-json\/wp\/v2\/media?parent=2732"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blog.trive.com\/es\/wp-json\/wp\/v2\/categories?post=2732"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blog.trive.com\/es\/wp-json\/wp\/v2\/tags?post=2732"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}